Literature DB >> 2426576

N-terminal deletions in Rous sarcoma virus p60src: effects on tyrosine kinase and biological activities and on recombination in tissue culture with the cellular src gene.

F R Cross, E A Garber, H Hanafusa.   

Abstract

We have constructed deletions within the region of cloned Rous sarcoma virus DNA coding for the N-terminal 30 kilodaltons of p60src. Infectious virus was recovered after transfection. Deletions of amino acids 15 to 149, 15 to 169, or 149 to 169 attenuated but did not abolish transforming activity, as assayed by focus formation and anchorage-independent growth. These deletions also had only slight effects on the tyrosine kinase activity of the mutant src protein. Deletion of amino acids 169 to 264 or 15 to 264 completely abolished transforming activity, and src kinase activity was reduced at least 10-fold. However, these mutant viruses generated low levels of transforming virus by recombination with the cellular src gene. The results suggest that as well as previously identified functional domains for p60src myristylation and membrane binding (amino acids 1 to 14) and tyrosine kinase activity (amino acids 250 to 526), additional N-terminal sequences (particularly amino acids 82 to 169) can influence the transforming activity of the src protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2426576      PMCID: PMC367017          DOI: 10.1128/mcb.5.10.2789-2795.1985

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  Identification of a transformation-specific antigen induced by an avian sarcoma virus.

Authors:  J S Brugge; R L Erikson
Journal:  Nature       Date:  1977-09-22       Impact factor: 49.962

2.  Protein kinase activity associated with the avian sarcoma virus src gene product.

Authors:  M S Collett; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

3.  Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein.

Authors:  A D Levinson; H Oppermann; L Levintow; H E Varmus; J M Bishop
Journal:  Cell       Date:  1978-10       Impact factor: 41.582

4.  Recombination between viral and cellular sequences generates transforming sarcoma virus.

Authors:  L H Wang; C C Halpern; M Nadel; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

5.  Changes in protein phosphorylation in Rous sarcoma virus-transformed chicken embryo cells.

Authors:  J A Cooper; T Hunter
Journal:  Mol Cell Biol       Date:  1981-02       Impact factor: 4.272

6.  Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus.

Authors:  B M Sefton; T Hunter; K Beemon; W Eckhart
Journal:  Cell       Date:  1980-07       Impact factor: 41.582

7.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

9.  Cellular information in the genome of recovered avian sarcoma virus directs the synthesis of transforming protein.

Authors:  R E Karess; W S Hayward; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

10.  Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine.

Authors:  M S Collett; A F Purchio; R L Erikson
Journal:  Nature       Date:  1980-05-15       Impact factor: 49.962

View more
  58 in total

1.  Src homology region 2 domains direct protein-protein interactions in signal transduction.

Authors:  M F Moran; C A Koch; D Anderson; C Ellis; L England; G S Martin; T Pawson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Multiple SH2-mediated interactions in v-src-transformed cells.

Authors:  C A Koch; M F Moran; D Anderson; X Q Liu; G Mbamalu; T Pawson
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

3.  The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function.

Authors:  C A Koch; M Moran; I Sadowski; T Pawson
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

4.  Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation.

Authors:  B J Mayer; H Hanafusa
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

5.  Two point mutations in the transmembrane domain of P68gag-ros inactive its transforming activity and cause a delay in membrane association.

Authors:  S M Jong; L H Wang
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Src homology domains of v-Src stabilize an active conformation of the tyrosine kinase catalytic domain.

Authors:  B Xu; W T Miller
Journal:  Mol Cell Biochem       Date:  1996-05-10       Impact factor: 3.396

7.  Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src.

Authors:  H Hirai; H E Varmus
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

8.  Requirement of phosphatidylinositol-3 kinase modification for its association with p60src.

Authors:  Y Fukui; H Hanafusa
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

9.  Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src.

Authors:  C Seidel-Dugan; B E Meyer; S M Thomas; J S Brugge
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

10.  Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases.

Authors:  S M Bell; D C Connolly; N J Maihle; J L Degen
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.